Insights into PK ‐Based Bridging for Products Using a Common Autoinjector Platform: A Review of 16 Autoinjectors in 14 Biological License Applications
- 14 April 2026
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (1) , 28-31
Abstract
An emerging proposal suggests that prior findings of pharmacokinetic comparability for one product could be applied to other therapeutic protein products that use the same autoinjector platform. We investigated 16 autoinjectors using one platform and found that (a) pharmacokinetic comparability outcomes varied and (b) these outcomes were not attributable to identified device performance parameters or product viscosity. Further investigations are necessary to support the proposed extrapolation across products sharing the same autoinjector platform.Keywords
This publication has 6 references indexed in Scilit:
- A Risk-Based Assessment for Determining the Pharmacokinetic Comparability Requirements of Biologic-Device Combination Products Administered by Subcutaneous InjectionThe AAPS Journal, 2024
- Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge GapClinical Pharmacology & Therapeutics, 2024
- A Review of Recent FDA-Approved Biologic-Device Combination ProductsJournal of Pharmaceutical Sciences, 2023
- A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability AssessmentPharmaceutical Research, 2023
- Formative and Validation Human Factors studies of a new disposable autoinjector for subcutaneous delivery of chronic disease therapiesExpert Opinion on Drug Delivery, 2021
- Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and AutoinjectorsThe AAPS Journal, 2020